CDK4/6 inhibitors, used as the initial endocrine treatment for metastatic HR+/HER2− breast cancer, have demonstrated an ability to boost tumor immunogenicity and work in conjunction with PD-1 blockade to improve antitumor efficacy[20,21]. Here, CDK4 is linked to neoplasm.